Raymond James analyst Danielle Brill maintained a Hold rating on Global Blood Therapeutics (GBT – Research Report) yesterday. The company’s

Raymond James analyst Danielle Brill maintained a Hold rating on Global Blood Therapeutics (GBT – Research Report) yesterday. The company’s
Global Blood Therapeutics (GBT – Research Report) received a Buy rating and a $75.00 price target from H.C. Wainwright analyst
In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Global Blood Therapeutics (GBT –
Wedbush analyst Liana Moussatos reiterated a Buy rating on Global Blood Therapeutics (GBT – Research Report) today and set a
In a report released today, Danielle Brill from Raymond James maintained a Buy rating on Global Blood Therapeutics (GBT –
In a report released yesterday, Mark Breidenbach from Oppenheimer assigned a Buy rating to Global Blood Therapeutics (GBT – Research
After Wedbush and Guggenheim gave Global Blood Therapeutics (NASDAQ: GBT) a Buy rating last month, the company received another Buy,